Rakovina Therapeutics Announces Q3 2025 Financial Results and Corporate Update
Rakovina Therapeutics reported a net loss of CAD 1,781,757 for the three months ended September 30, 2025 (Q3 2025).
Research and development expenses were CAD 1,102,371, reflecting ongoing advancement of AI-powered drug candidates.
General and administrative expenses totaled CAD 539,174, including investor relations and exchange fees.
Cash and cash equivalents stood at CAD 822,293 as of September 30, 2025.
The company presented new pre-clinical data at the AACR-NCI-EORTC International Conference showing that its AI-discovered ATR inhibitor program (kt-5000 series) achieved potent ATR inhibition and confirmed CNS penetration, a notable differentiator in the DDR inhibitor space.
Rakovina's senior management attended the H.C. Wainwright 27th Annual Global Investment Conference in early September 2025 to engage with investors and potential pharmaceutical partners.
The company achieved DTC eligibility in July 2025, expanding U.S. investor access.
Rakovina highlighted strategic collaborations, including the NanoPalm joint-venture initiative, and multiple scientific presentations at leading oncology meetings during 2025.
The company views these achievements as positioning it for growth and to bring transformative cancer therapies forward, bolstered by its AI-enabled DDR pipeline.